On Friday, Aldeyra Therapeutics Inc (NASDAQ: ALDX) was 8.57% up from the session before settling in for the closing price of $2.45. A 52-week range for ALDX has been $1.14 – $7.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at -2.98%. With a float of $58.15 million, this company’s outstanding shares have now reached $60.05 million.
The firm has a total of 9 workers. Let’s measure their productivity. In terms of profitability, gross margin is 49.89%, operating margin of -25007.82%, and the pretax margin is -23596.19%.
Aldeyra Therapeutics Inc (ALDX) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Aldeyra Therapeutics Inc stocks. The insider ownership of Aldeyra Therapeutics Inc is 2.92%, while institutional ownership is 56.16%. The most recent insider transaction that took place on Apr 03 ’25, was worth 4,828,000. In this transaction 10% Owner of this company sold 3,400,000 shares at a rate of $1.42, taking the stock ownership to the 5,875,851 shares. Before that another transaction happened on Aug 12 ’24, when Company’s Chief Development Officer sold 16,041 for $4.74, making the entire transaction worth $75,975. This insider now owns 236,771 shares in total.
Aldeyra Therapeutics Inc (ALDX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -2.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.10% during the next five years compared to 15.99% growth over the previous five years of trading.
Aldeyra Therapeutics Inc (NASDAQ: ALDX) Trading Performance Indicators
You can see what Aldeyra Therapeutics Inc (ALDX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.97, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach 0.11 in one year’s time.
Technical Analysis of Aldeyra Therapeutics Inc (ALDX)
Analysing the last 5-days average volume posted by the [Aldeyra Therapeutics Inc, ALDX], we can find that recorded value of 0.76 million was lower than the volume posted last year of 1.24 million. As of the previous 9 days, the stock’s Stochastic %D was 89.42%. Additionally, its Average True Range was 0.21.
During the past 100 days, Aldeyra Therapeutics Inc’s (ALDX) raw stochastic average was set at 25.08%, which indicates a significant decrease from 98.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.45% in the past 14 days, which was lower than the 232.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.62, while its 200-day Moving Average is $4.81. Now, the first resistance to watch is $2.73. This is followed by the second major resistance level at $2.80. The third major resistance level sits at $2.93. If the price goes on to break the first support level at $2.53, it is likely to go to the next support level at $2.40. Now, if the price goes above the second support level, the third support stands at $2.33.
Aldeyra Therapeutics Inc (NASDAQ: ALDX) Key Stats
There are 59,896K outstanding shares of the company, which has a market capitalization of 159.32 million. As of now, sales total 0 K while income totals -55,850 K. Its latest quarter income was 0 K while its last quarter net income were -9,930 K.
